Alk-Abello AS (LTS:0OIR) Debt-to-Asset : 0.07 (As of Sep. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Alk-Abello AS Debt-to-Asset?

Alk-Abello AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr66 Mil. Alk-Abello AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr444 Mil. Alk-Abello AS's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was kr7,149 Mil. Alk-Abello AS's debt to asset for the quarter that ended in Sep. 2024 was 0.07.

Alk-Abello AS Debt-to-Asset Historical Data

The historical data trend for Alk-Abello AS's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS Debt-to-Asset Chart

Alk-Abello AS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.18

0.17

0.12

0.11

Alk-Abello AS Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															0.11	0.11	0.08	0.07	0.07

Competitive Comparison of Alk-Abello AS's Debt-to-Asset

For the Biotechnology subindustry, Alk-Abello AS's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alk-Abello AS's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Alk-Abello AS's Debt-to-Asset falls into.

Alk-Abello AS Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Alk-Abello AS's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(326	+	439)	/	6726
	=	0.11

Alk-Abello AS's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(66	+	444)	/	7149
	=	0.07

Alk-Abello AS (LTS:0OIR) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Alk-Abello AS Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Alk-Abello AS's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Alk-Abello AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (LTS:0OIR) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

AKBLF:USA ALKBc:UK ALK B:Denmark 4AJ0:Germany

Address

Boge Alle 6-8, Horsholm, DNK, DK-2970

Website

https://www.alk.net

Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

Alk-Abello AS Headlines

No Headlines